CircNova, Inc. is a biotechnology company that specializes in the development of circular RNA (circRNA) therapeutics, utilizing its proprietary AI NovaEngine™. This innovative platform employs generative artificial intelligence to predict circular RNA structures through deep learning, enabling the design of therapeutic candidates aimed at previously undruggable diseases, such as Triple-negative Breast Cancer. The company focuses on non-coding RNA, which has various mechanisms of action against challenging disease targets, and is committed to building a robust intellectual property portfolio to support the advancement of circRNA-based therapies.

The technology at CircNova integrates AI-guided RNA folding and active structure prediction with high-throughput RNA synthesis, significantly enhancing the efficiency of therapeutic development. This approach not only streamlines the drug discovery process but also opens new avenues for addressing major unmet clinical needs. CircNova's mission is driven by a commitment to continuous learning and innovation, fostering collaborations with leading research institutions to further advance its capabilities in RNA-based therapies.

United States

CircNova, Inc. is a biotechnology company that leverages our unique AI NovaEngine™ to generate, analyze and identify circular RNA for therapeutic development.

CircNova

Company Details